PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperphosphatemia |
| Phenotype | C1561644|chronic kidney disease (ckd) |
| Sentences | 12 |
| PubMedID- 24445424 | Purpose of review: the review focuses on the rationale and evidence behind management strategies for hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 25134623 | Calcium-based binders have been a standard treatment for hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 25079863 | Background: lanthanum carbonate (lc), an effective non-calcium phosphate binder is widely used to manage hyperphosphatemia in patients with chronic kidney disease (ckd) on dialysis. |
| PubMedID- 25815172 | Increased cardiovascular morbidity and mortality has been associated with the hyperphosphatemia seen in patients with end-stage chronic kidney disease (ckd). |
| PubMedID- 21324193 | Background: hyperphosphatemia in patients with chronic kidney disease (ckd) contributes to secondary hyperparathyroidism, soft tissue calcification, and increased mortality risk. |
| PubMedID- 19955298 | Objective: to review the pharmacology, pharmacokinetics, clinical efficacy, safety data, and place in therapy of sevelamer carbonate for the treatment of hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 25995642 | A series of studies were designed to assess the efficacy of sevelamer on hyperphosphatemia in chronic kidney disease (ckd) patients on dialysis in people’s republic of china.8–15 chen et al8 performed a randomized, double-blind, dose-titration study which compared sevelamer carbonate (starting dose 800 mg three times daily) with placebo over 8 weeks’ duration in chinese ckd patients on hd. |
| PubMedID- 24000048 | hyperphosphatemia in chronic kidney disease (ckd) has been associated with elevated cardiovascular morbidity and mortality. |
| PubMedID- 25341358 | Ferric citrate hydrate was recently approved in japan as an oral phosphate binder to be taken with food for the control of hyperphosphatemia in patients with chronic kidney disease (ckd). |
| PubMedID- 20827429 | In clinical practice, 1,25-(oh)2d3 is widely used in the treatment of hypocalcemia and hyperphosphatemia of patients with chronic kidney disease (ckd). |
| PubMedID- 25017110 | Sbr759 is a novel polynuclear iron(iii) oxide-hydroxide starch.sucrose.carbonate complex being developed for oral use in chronic kidney disease (ckd) patients with hyperphosphatemia on hemodialysis. |
| PubMedID- 20438515 | Lanthanum carbonate is a non-calcium-based phosphate binder for hyperphosphatemia in patients with chronic kidney disease (ckd). |
Page: 1